Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy
Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
A subset of patients with NAFLD that have not been extensively studied are those infected
with human immunodeficiency virus (HIV). Currently, there is no FDA approved treatment for
NAFLD or NASH. Additionally, there have been no significant clinical trials for HIV patients
with NAFLD and there are no approved treatment options. We plan to conduct a randomized,
double-blinded, placebo-controlled clinical trial to examine the efficacy of 600 mg of
Aramchol daily (including 200 mg tablet and 400 mg tablet) versus identical placebo given
over 12 weeks to improve HIV-associated hepatic steatosis as measured by a validated and
accurate magnetic resonance imaging (MRI)-based technique.